Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DNCL002273

Drug Information
CompanyOXiGENE South San Francisco, CA
IndicationAML, myelodysplastic syndromes
[ICD9: 205.0, 238.7   ICD10: C92.0, D46]
Phase I    
Refractory AML
[ICD9: 205.0   ICD10: C92.0]
Phase I    

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Canonical SMILESCOC1=C(C(=C(C=C1)C=CC2=CC(=C(C(=C2)OC)OC)OC)OP(=O)(O)O)OP(=O)(O)O.[Na+].
Isomeric SMILESCOC1=C(C(=C(C=C1)/C=C\C2=CC(=C(C(=C2)OC)OC)OC)OP(=O)(O)O)OP(=O)(O)O.[Na+
PubChem Compound IDCID 56841628.


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543